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ABSTRACT
Objective To investigate the association between
echocardiographic measurements with emphasis on
diastolic dysfunction and risk of atrial ﬁbrillation (AF) in
a population-based cohort study.
Methods We followed 2406 participants from the
Tromsø Study from 1994 to 2010. Left atrial (LA) size
and mitral Doppler indices as measured by
echocardiography were used for evaluating diastolic
dysfunction. Information concerning age, systolic blood
pressure, height, heart rate, body mass index, total and
high-density lipoprotein cholesterol, self-reported use of
alcohol, smoking, coffee, physical activity,
antihypertensive treatment, prevalent coronary heart
disease, valvular heart disease, heart failure,
hypertrophy, diabetes and palpitations were obtained at
baseline. The outcome measure was clinical AF,
documented by an ECG.
Results AF was detected in 462 subjects (193
women). Mean age at baseline was 62.6 years.
Incidence rate of clinical AF was 12.6 per 1000 person-
years. In multivariable Cox proportional hazards
regression analysis, moderately enlarged LA was
associated with 60% (95% CI 1.2 to 2.0) increased risk
of AF. Severely enlarged LA had HR for AF of 4.2 (95%
CI 2.7 to 6.5) with p value for linear trend <0.001, and
the association was similar in both sexes. Abnormal
mitral Doppler ﬂow adjusted for predictor variables did
not show a statistically signiﬁcant association with AF
risk. However, when LA size was also adjusted for, the
risk of AF increased by 30% (95% CI 1.0 to 1.6).
Conclusions Our ﬁndings suggest that enlarged LA as
a measure for diastolic dysfunction is a signiﬁcant risk
factor for AF in both sexes, and adding measures of
abnormal diastolic ﬂow increased the predictive ability
signiﬁcantly.
INTRODUCTION
Atrial ﬁbrillation (AF) is a common arrhythmia and
is associated with increased mortality and morbid-
ity.1 2 It increases the risk of stroke and heart
failure, affecting quality of life and cognition.2 3
Established risk factors for AF include advancing
age, male sex, hypertension, diabetes mellitus, cor-
onary heart disease (CHD), hyperthyroidism,
inﬂammation, obesity, diastolic dysfunction and
stroke.4 5 The Framingham study found that
enlarged left atrial (LA) size is associated with
increased risk of AF in both sexes aged 59–
90 years.6 The ARIC study found a higher preva-
lence of AF in people with dilated LA.7 Another
study on subjects aged 65 years and above found
that LV diastolic dysfunction predicted AF.8 The
Framingham study conﬁrmed this ﬁnding in people
with mean age of 75 years.9 Among patients with
acute myocardial infarction (MI) and reduced LV
systolic function, diastolic dysfunction was asso-
ciated with increased risk of AF.10 However, these
risk factors need to be validated in large cohorts
with longer follow-ups.
Our aim was to investigate the association
between echocardiographic measurements with
emphasis on diastolic dysfunction and risk of inci-
dent clinical AF in the population-based Tromsø
Study with 16 years of follow-up.
METHODS
Study population
The Tromsø Study is a Norwegian prospective
cohort study.11 It was initiated in 1974 with an
emphasis on the epidemiology of cardiovascular
diseases. In the fourth survey (Tromsø 4) in 1994–
1995, all inhabitants 25 years or older were invited
and 27 158 people (77% of the eligible population)
participated. Among them, all individuals aged 55–
74 years and 5%–10% samples of the other age
groups (aged 25–54 and 75–84 years) were invited
for a second visit, which included extensive exami-
nations. The 6902 individuals who attended were
randomly allocated to one of two lines of examin-
ation. One of the lines included echocardiog-
raphy.12 The attendance rate was 88%.13 Figure 1
shows that after exclusion, 2406 participants were
included. The survey complies with the Declaration
of Helsinki, and was approved by the Regional
Committee for Medical and Health Research
Ethics, the Data Inspectorate and the Norwegian
Directorate of Health.
Baseline characteristics
Questionnaire data were used for predictor vari-
ables on alcohol consumption (no alcohol/low
alcohol intake (0–4 times/month)/high alcohol
intake (≥5 times/month)), coffee consumption
(cups/day), smoking (current/previous/never), dia-
betes (yes/no), antihypertensive treatment (current/
previous/never), palpitations (yes/no), prevalent
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CHD (yes/no), thyroid disease (yes/no) and physical activity
(active (weekly exercise with sweating or being out of breath or
≥3 h per week of light exercise without sweating or being out
of breath) and inactive (<3 h per week of activity without
sweating or being out of breath)).14 Prevalent CHD was deﬁned
as self-reported previous MI. Body mass index (BMI) was calcu-
lated as weight/height2 (kg/m2) and body surface area (BSA) was
calculated by Du Bois formula (BSA=(weight (kg)0.425×height
(cm)0.725)×0.007184). Blood pressure and heart rate were
recorded three times with 1 min intervals after 2 min resting,
using an automatic device (Dinamap Vital Signs Monitor 1846,
Critikon), and the mean from the second and third reading was
used. Hypertension was deﬁned as systolic blood pressure (SBP)
≥140 mm Hg or diastolic blood pressure ≥90 mm Hg or use of
antihypertensive medication. Non-fasting total cholesterol was
analysed by enzymatic methods with commercial kits, and
serum high-density lipoprotein cholesterol was measured after
the precipitation of low-density lipoprotein with heparin and
manganese chloride. All blood sample analyses were performed
at the Department of Clinical Chemistry, University Hospital of
North Norway.
Echocardiography
Echocardiography was performed by two expert cardiologists
using a VingMed CFM 750 (VingMed Sound A/S, Horten,
Norway) with a combined 3.25 MHz mechanical and 2.5 MHz
Doppler probe. The examinations were performed using the
standard apical and parasternal long and short axis views.
Standard 2D-guided M-mode registrations of anteroposterior
LA size, internal dimensions of the LV and wall-thickness of the
septum and posterior wall were made from leading-edge-to-
leading-edge convention.15
The measurements of peak ﬂow velocity in early diastole
(E-wave) and during atrial contraction (A-wave), peak E/A ratio
and the E-wave deceleration time (EDT) were done online in
one heart cycle. The inﬂuence of heart rate was minimised by
measuring EDT as the time between the peak E-wave and the
upper deceleration slope extrapolated to the zero baselines.13
LA size was indexed by BSA. Valvular heart disease was deﬁned
as mitral insufﬁciency grade 3 (>7 cm2), heart failure as LVEF
<0.5 and hypertrophy as LV posterior wall end diastole
M-mode >1.4 cm and/or interventricular septum end diastole
M-mode >1.4 cm.
Reproducibility
A reproducibility study of the echocardiographic data was per-
formed in a subsample of 58 subjects who were examined twice
with 1-week interval by both cardiologists. For the E-wave, the
mean differences ±SD were −0.001±0.117, 0.025±0.096 and
0.034±0.078 m/s for intraobserver cardiologist 1, intraobserver
cardiologist 2 and interobserver pairs, respectively. For the
A-wave, the corresponding values were −0.008±0.091, 0.031
±0.156 and −0.003±0.084 m/s. For the E/A ratio, the values
were 0.015±0.29, 0.007±0.28 and 0.056±0.19, and for the
deceleration time, −0.001±0.034, −0.001±0.030 and −0.009
±0.036 s.13
Classiﬁcation of diastolic dysfunction
We used LA size and mitral Doppler indices for evaluating dia-
stolic dysfunction. Diastolic dysfunction was classiﬁed according
to current guidelines,16 and the cut-off values for E/A ratios and
EDTwere set with slight adjustments, consistent with the values
in a previous community-based study.17
Figure 1 Flow chart, the Tromsø
Study, 1994–2010. AF, atrial
ﬁbrillation.
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Mitral Doppler indices
Mitral Doppler indices are classiﬁed according to increasing
degree of diastolic dysfunction as follows:
Group I: E/A ratio 0.75–1.5 and EDT ≥140 ms
Group II: E/A ratio >1.5 and EDT >140 ms
Group III : E/A ratio <0.75 and any EDT
Group IV: E/A ratio >0.75 and EDT <140 ms
Also, mitral Doppler indices are classiﬁed as:
Normal: E/A ratio 0.75–1.5 and EDT ≥140 ms
Abnormal: E/A ratio <0.75 or >1.5 or EDT <140 ms
LA size
LA size was indexed by BSA and categorised into three groups
as normal (<2.2 cm/m2), moderately enlarged (2.2–2.79 cm/m2)
and severely enlarged (≥2.8 cm/m2).18
Mitral Doppler indices and LA size combined
Mitral Doppler indices and LA size combined into six groups as
follows:
Group 1=LA size <2.2 and normal mitral Doppler indices
Group 2=LA size <2.2 and abnormal mitral Doppler indices
Group 3=LA size 2.2–2.79 and normal mitral Doppler indices
Group 4=LA size 2.2–2.79 and abnormal mitral Doppler
indices
Group 5=LA size ≥2.8 and normal mitral Doppler indices
Group 6=LA size ≥2.8 and abnormal mitral Doppler indices
Endpoints
All participants were followed with respect to incident clinical
AF documented by an ECG. Norway has a personal identiﬁca-
tion number that allows exact matching of population register
data. The identiﬁcation number of participants of the 1994–
1995 study was linked to the diagnosis registry at the University
Hospital of North Norway (outpatient clinic included) and to
the National Causes of Death Registry at Statistics Norway,
using the following diagnostic codes: ICD-9 codes 427.0–
427.99 and ICD-10 codes I47 and I48. For participants with
diagnosis of cerebrovascular or cardiovascular events but
without a diagnosis of arrhythmia, paper versions of hospital
records (used until 2001) for notes on AF were manually
searched, and text searches with the term ‘atrial ﬁbrillation’
were performed in the electronic records. An independent end-
point committee adjudicated the events. All AF types were
merged in the analyses. Subjects with transient AF only during
acute MI or cardiac surgery and people with AF only in the last
week of life were not classiﬁed with AF. We followed 2406 par-
ticipants (ﬁgure 1) until the date of ﬁrst documented AF or date
of censoring due to death, migration or end of follow-up on 31
December 2010, whichever came ﬁrst. Those who had died or
emigrated during follow-up were identiﬁed through the
Population Registry of Norway.
Statistical analysis
We present the characteristics of the study population with and
without AF as means and SDs for continuous variables and pro-
portions of group total for categorical variables. Sex-speciﬁc
HRs for AF were estimated by multivariable Cox proportional
hazards regression models adjusted for age, height, BMI, hyper-
tension, palpitations and diabetes. The variables that were
included in the ﬁnal multivariable model were chosen based on
prior scientiﬁc knowledge19 or because they were signiﬁcant for
either sex in current univariable analyses for atrial size. We
tested for interactions between main independent variables
(atrial size, mitral Doppler indices group) and sex. We excluded
those with colinearity (tolerance <0.10) from the ﬁnal model.
The variable hypertension (yes/no) was used, and the variable
antihypertensive treatment and SBP were not included in the
multivariable models as it rendered similar information.
Similarly, when colinearity was tested with all the variables, the
tolerance was very low for BSA (tolerance=0.004; variance
inﬂation factor (VIF)=234.03); thus, only height was included.
Due to few cases in each category, prevalent cardiovascular dis-
eases (CHD, valvular heart disease, hypertrophy and heart
failure) were not adjusted for. The proportional hazard assump-
tion was validated with visual inspection of log-minus-log plots.
We calculated the c-statistic of the model to predict its clinical
usefulness for distinguishing high-risk from low-risk subjects
and log-likelihood ratio test to evaluate whether addition of
another variable improved the predictive ability signiﬁcantly. A
two-sided p value <0.05 was considered statistically signiﬁcant.
Statistical analysis was performed using STATA V.12 (Stata,
College Station, Texas, USA).
RESULTS
Incident clinical AF was identiﬁed in 193 women (15.6%) and
269 men (23%) (ﬁgure 1). The incidence rate of clinical AF per
1000 person-years was 11.2 in women and 17.5 in men.
Table 1 shows the baseline characteristics for subjects with and
without AF. Participants developing AF were signiﬁcantly older,
had higher blood pressure, total cholesterol, BMI and BSA,
higher prevalence of CHD, diabetes, palpitations, valvular heart
disease, heart failure, hypertrophy and taking antihypertensive
treatment. They also had higher LV mass, LA size, E/A ratio and
deceleration time. Women with subsequent AF consumed little
alcohol and were less physically active.
Table 2 gives the HRs for AF according to indexed LA size
categories, mitral Doppler groups and for abnormal mitral
Doppler ﬂow. The risk of AF increased with increasing atrial
size. In multivariable Cox proportional hazards regression ana-
lysis (model 2), a moderately enlarged LA was associated with
60% (95% CI 1.2 to 2.0) increased risk of AF compared with
subjects with normal LA size. In subjects with severely enlarged
LA, HR for AF was 4.2 (95% CI 2.7 to 6.5) compared with
subjects with normal LA size (p value for linear trend
<0.0001). The result was unchanged after adjustment for
abnormal mitral Doppler ﬂow (model 3) or mitral Doppler
groups (model 4) or when excluding those with baseline CHD,
valvular heart disease, heart failure or hypertrophy (model 5).
There were no associations between AF and abnormal mitral
Doppler ﬂow or AF and mitral Doppler groups (model 2) when
LA size was not adjusted for. When LA size was adjusted for
(model 4), abnormal mitral Doppler ﬂow was associated with
30% (95% CI 1.0 to 1.6) increased risk of AF compared with
subjects with normal mitral Doppler ﬂow.
Analysis of c-statistics revealed that the model with LA size
and all predictor variables together gave better prediction than a
model adjusted for only age and sex (Harrell’s c=0.71 vs 0.67,
p<0.0001) or a model with all predictors and mitral Doppler
groups/ﬂow (Harrell’s c=0.71 vs 0.69, p=0.001). The
c-statistics comparing the model with only age and sex to a
model with all predictors and mitral Doppler groups/ﬂow were
Harrell’s c=0.69 vs 0.67, p=0.001.
We also calculated the log-likelihood ratio χ2 statistics to
compare the predictive ability of the models. When LA size was
added to a model with only baseline characteristics, the model
improved signiﬁcantly (p<0.0001). Comparing baseline
characteristics with mitral Doppler ﬂow or mitral Doppler
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groups added to it, the p values were 0.1 in both situations.
Thus, the model with LA size predicted AF better than the
other models.
Figure 2 shows the Kaplan–Meier curves for AF among differ-
ent categories of LA size and mitral Doppler indices. Those
with larger LA size and abnormal mitral Doppler indices have
increased risk of AF. When these two risk factors were com-
bined, the risk of AF increased with increasing LA size and
abnormal mitral Doppler indices (ﬁgure 3). We combined group
5 and 6 due to few cases of AF in each category.
Table 3 shows the sex-speciﬁc HRs for AF according to LA
size, and mitral Doppler ﬂow and LA size combined. In subjects
with severely enlarged LA, HRs for AF were 4.5 (95% CI 2.6 to
8.0) in women and 3.6 (95% CI 1.7 to 7.5) in men compared
with subjects with normal LA size (p value for linear trend
<0.0001). The associations were similar in both sexes (p value
for interaction=0.28). Adjustment for covariates in a multivari-
able model (model 2) increased HRs, whereas in model 3,
excluding participants with baseline CHD, valvular heart
disease, heart failure or hypertrophy, attenuated the strength of
the relationship slightly in both women and men. Model 4
shows the HRs for AF according to mitral Doppler ﬂow and LA
size combined. In this model, the risk of AF increased with
increasing atrial size and abnormal mitral Doppler ﬂow com-
pared with normal mitral Doppler ﬂow. In multivariable Cox
proportional hazards regression analysis (model 5), in subjects
with severely enlarged LA and abnormal mitral Doppler ﬂow,
HR for AF was 3.7 (95% CI 1.6 to 8.7) compared with those
Table 1 Unadjusted baseline characteristics of women and men by incident clinical AF during follow-up
Baseline characteristics
Women with Men with
AF (n=193) No AF (n=1043) AF (n=269) No AF (n=901)
Age (years) 66.4 (5.7) 62.5 (6.0) 64.2 (6.3) 61.5 (6.4)
Systolic blood pressure (mm Hg) 157.1 (23.8) 145.2 (22.7) 148.7 (22.7) 145.3 (19.9)
Diastolic blood pressure (mm Hg) 86.2 (14.4) 82.2 (12.3) 86.2 (12.5) 85.4 (11.4)
Heart rate (beats/min) 73.9 (13.7) 75.2 (11.6) 69.9 (13.2) 71.4 (12.5)
Height (cm) 161.6 (6.7) 161.1 (6.1) 175.3 (7.1) 174.7 (6.6)
Body mass index (kg/m2) 27.9 (5.2) 26.0 (4.3) 26.9 (3.6) 25.9 (3.2)
BSA (m2) 1.8 (0.2) 1.7 (0.1) 2.0 (0.2) 1.9 (0.2)
Total cholesterol (mmol/L) 7.13 (1.13) 7.08 (1.24) 6.58 (1.14) 6.57 (1.19)
HDL cholesterol (mmol/L) 1.67 (0.45) 1.68 (0.42) 1.40 (0.39) 1.44 (0.40)
Alcohol, % (n)
No alcohol 37.2 (71) 30.4 (315) 13.8 (37) 13.6 (122)
Low alcohol intake (0–4 times/month) 61.3 (117) 61.8 (641) 65.7 (176) 65.4 (587)
High alcohol intake (≥5 times/month) 1.6 (3) 7.9 (82) 20.5 (55) 21.0 (188)
Smoking, % (n)
No Smoking 48.2 (93) 45.9 (479) 21.2 (57) 17.3 (156)
Previous smoking 25.9 (50) 24.6 (257) 50.2 (135) 47.3 (426)
Current smoking 25.9 (50) 29.4 (307) 28.6 (77) 35.4 (319)
Coffee (cups/day) 4.9 (2.4) 4.8 (2.7) 5.7 (3.6) 6.1 (3.7)
Physical activity, % (n) 43.5 (84) 53.4 (557) 66.5 (179) 67.4 (607)
Hypertension, % (n) 80.8 (156) 58.5 (610) 70.6 (190) 60.8 (548)
Antihypertensive treatment, % (n) 25.9 (50) 12.2 (127) 22.4 (60) 10.3 (92)
Coronary heart disease, % (n) 6.3 (12) 2.6 (27) 15.3 (41) 6.6 (59)
Valvular heart disease, % (n) 1.0 (2) 0.3 (3) 1.1 (3) 0.0 (0)
Heart failure, % (n) 0.7 (1) 0.3 (3) 4.3 (9) 1.5 (11)
Hypertrophy, % (n) 2.0 (3) 0.7 (6) 3.8 (8) 2.4 (18)
Diabetes, % (n) 5.2 (10) 2.4 (25) 5.2 (14) 2.6 (23)
Palpitations, % (n) 38.1 (56) 29.7 (260) 24.4 (59) 15.0 (124)
Thyroid disease, % (n) 15.3 (21) 10.5 (90) 1.7 (4) 1.9 (15)
LVM indexed by height (g/m1.7) 77.3 (22.1) 68.8 (17.8) 90.4 (26.7) 79.0 (21.3)
LVM indexed by BSA (g/m2) 99.3 (26.3) 90.8 (21.5) 118.1 (32.9) 105.0 (26.4)
LA size indexed by BSA (cm/m2) 2.4 (0.4) 2.2 (0.3) 2.2 (0.3) 2.1 (0.3)
E/A ratio 0.96 (0.30) 0.97 (0.25) 1.01 (0.40) 0.99 (0.27)
Deceleration time (dt) 207.3 (49.5) 196.4 (39.7) 210.7 (48.1) 206.4 (43.0)
Mitral Doppler groups, % (n)
Group I 71.7 (137) 75.5 (773) 69.2 (182) 78.5 (695)
Group II 2.6 (5) 2.7 (28) 4.9 (13) 3.8 (34)
Group III 22.0 (42) 19.4 (199) 24.0 (63) 15.9 (141)
Group IV 3.7 (7) 2.3 (24) 1.9 (5) 1.7 (15)
Abnormal mitral Doppler flow
Group II–IV, % (n)
28.3 (54) 24.5 (251) 30.8 (81) 21.5 (190)
The Tromsø Study, 1994–2010.
Mitral Doppler groups: Group I E/A ratio 0.75–1.5 and EDT ≥140 ms; group II E/A ratio >1.5 and EDT >140 ms; group III E/A ratio <0.75 and any EDT; group IV E/A ratio >0.75 and
EDT <140 ms.
AF, atrial fibrillation; BSA, body surface area; EDT, E-wave deceleration time; HDL, high-density lipoprotein; LA, left atrium; LVM, LV mass.
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with normal LA size and mitral Doppler ﬂow. We did not
perform sex-speciﬁc analyses due to few cases of AF in each cat-
egory. The predicted c-statistic for model 5 compared with the
model with only age and sex had better predictive ability
(Harrell’s c=0.71 vs 0.67, p<0.0001). Also, log-likelihood ratio
χ2 statistics comparing the model with the combined variable
(model 5) with a model comprising only baseline characteristics
(age, sex, height, BMI, hypertension, diabetes and palpitation),
the model with the combined variable gave a signiﬁcantly better
ﬁt (p<0.0001).
DISCUSSION
In this population-based study, we found that the risk of clinical
AF increased with increasing LA size in both sexes when
adjusted for other known risk factors. There was an increased
risk of AF among subjects with abnormal mitral Doppler indices
Table 2 HR (95% CI) for atrial fibrillation according to indexed left atrial (LA) size, mitral Doppler groups and mitral Doppler flow
All Model 1 Model 2 Model 3 Model 4 Model 5
Indexed LA size
1 (<2.2) 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
2 (2.2–2.79) 1.4 (1.1 to 1.7) 1.6 (1.2 to 2.0) 1.6 (1.3 to 2.0) 1.6 (1.2 to 2.0) 1.4 (1.1 to 1.8)
3 (≥2.8) 3.1 (2.1 to 4.4) 4.2 (2.7 to 6.5) 4.2 (2.7 to 6.5) 4.1 (2.6 to 6.4) 4.0 (2.5 to 6.4)
(p for trend <0.0001) (p for trend <0.0001) (p for trend <0.0001) (p for trend <0.0001) (p for trend <0.0001)
Mitral Doppler groups
Group I 1 (Ref.) 1 (Ref.) 1 (Ref.) – 1 (Ref.)
Group II 1.6 (1.0 to 2.7) 1.8 (1.1 to 3.0) 1.5 (0.9 to 2.6) 1.6 (0.9 to 2.9)
Group III 1.1 (0.9 to 1.4) 1.1 (0.9 to 1.4) 1.2 (0.9 to 1.6) 1.1 (0.9 to 1.5)
Group IV 1.7 (1.0 to 3.0) 1.5 (0.8 to 3.1) 1.5 (0.7 to 2.9) 1.2 (0.5 to 3.0)
(p Value for trend 0.103) (p Value for trend 0.141) (p Value for trend 0.051) (p Value for trend 0.240)
Abnormal mitral Doppler flow 1.2 (1.0 to 1.5) 1.2 (1.0 to 1.5) – 1.3 (1.0 to 1.6) 1.2 (0.9 to 1.5)
(Group II–IV) (p Value 0.081) (p Value 0.086) (p Value 0.034) (p Value 0.159)
The Tromsø Study, 1994–2010.
Model 1: adjusted for age and sex.
Model 2: as Model 1+height, body mass index, hypertension, diabetes, palpitation.
Model 3: as Model 2+abnormal mitral Doppler flow (only in indexed LA size), LA size (only in mitral Doppler groups and flow).
Model 4: as Model 2+mitral Doppler groups (only in indexed LA size) or LA size (only in mitral Doppler groups and flow).
Model 5: as Model 2, participants with coronary heart disease, valvular heart disease, heart failure or hypertrophy at baseline excluded.
Mitral Doppler groups: Group I E/A ratio 0.75–1.5 and E-wave deceleration time (EDT >140 ms; group II E/A ratio >1.5 and EDT >140 ms; group III E/A ratio <0.75 and any EDT; group
IV E/A ratio >0.75 and EDT <140 ms.
Ref; reference.
Figure 2 Kaplan–Meier curves for atrial ﬁbrillation (AF): (a)
categories of left atrial (LA) size and (b) categories of mitral Doppler
indices. The Tromsø Study, 1994–2010.
Figure 3 Kaplan–Meier curves for atrial ﬁbrillation (AF) categories of
left atrial (LA) size and mitral Doppler indices combined. The Tromsø
Study, 1994–2010. Group 1=LA size <2.2 cm/m2 and normal mitral
Doppler indices (n=947). Group 2=LA size <2.2 cm/m2 and abnormal
mitral Doppler indices (n=294). Group 3=LA size 2.2–2.79 cm/m2 and
normal mitral Doppler indices (n=720). Group 4=LA size 2.2–
2.79 cm/m2 and abnormal mitral Doppler indices (n=227). Group 5=LA
size ≥2.8 cm/m2 and normal/abnormal mitral Doppler indices (n=92).
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accompanied by enlarged LA. However, there was no associ-
ation between unadjusted diastolic dysfunction based on mitral
Doppler indices and AF risk.
The incidence rate of clinical AF was higher in our study
compared with another study done in a similar setting, which
could be due to slightly older participants.19
Left atrium size
Some previous studies have found higher risk of AF among
those with larger LA.6 8 20–24 A cross-sectional study
showed higher prevalence of AF (15%) among those with
dilated LA compared with those with normal-sized LA
(11%).7 LA size does not change with ageing, thus enlarge-
ment is an expression of pathology.25 LA enlargement is due
to the change in ﬁlling dynamics associated with abnormal
LV relaxation. This results in decreased passive emptying
volume from the LA to the LV and decreased direct ﬂow
volume from pulmonary veins into the LV in early dia-
stole.21 To compensate, active LA contraction is enhanced,
increasing the active emptying volume in late diastole.21
This preserves LV stroke volume, but it also enlarges the LA
predisposing to AF.21
A prospective study showed that indexing LA by height was
non-signiﬁcantly better than BSA. We have indexed LA by BSA, as
there are no established cut-off values for indexation by height.26
Mitral Doppler indices
We found no independent association between increasing degree
of diastolic dysfunction based on mitral Doppler indices and AF.
This is in contrast to a study from Minnesota, with participants
aged 65 years or older, which found a positive relationship
between mitral Doppler indices and AF risk.8 Age differences
may explain the divergent results, as our study was performed
among people 50 years and above. The classiﬁcation of diastolic
dysfunction may be less precise in the middle age groups as the
E/A ratio is high and DT is low in young and middle-aged
adults compared with older people.13 27 A study among patients
post MI with depressed LV systolic function also found higher
risk of AF with diastolic dysfunction.10
Our ﬁnding of an increased AF risk among subjects with
abnormal mitral Doppler ﬂow accompanied by enlarged LA is
supported by others.21 28 The mitral Doppler indices reﬂect a
snapshot of diastolic function, and the pattern can change if
loading condition changes whereas LA size reﬂects the chron-
icity of the loading conditions. Thus, LA size provides a long-
term view of the condition regardless of loading condition
during examination.29 LA size increases with worsening diastolic
dysfunction, independent of other risk factors.30
Strengths
Our study was performed in a large population-based cohort of
both sexes 50 years and older, with a high attendance rate and a
long follow-up. Previous studies have been performed in sub-
groups of elderly subjects with prevalent disease or with shorter
follow-up.6 8–10
Another strength was the case validation and search methods.
The hospital discharge list may be incomplete. Through system-
atic hospital record search, we found people who were not
registered with AF, but where ECG or medical texts
Table 3 Sex-specific HR (95% CI) for atrial fibrillation according to left atrial (LA) size, and mitral Doppler flow and left atrial size combined
Indexed left atrial size
p Value for trend1 (<2.2) 2 (2.2 to 2.79) 3 (≥2.8)
Women
Events (n=177) n=61 n=89 n=27
Model 1 1 (Ref.) 1.5 (1.1 to 2.1) 3.0 (1.9 to 4.9) <0.0001
Model 2 1 (Ref.) 1.6 (1.1 to 2.3) 4.5 (2.6 to 8.0) <0.0001
Model 3 1 (Ref.) 1.5 (1.0 to 2.3) 4.4 (2.4 to 8.0) <0.0001
Men
Events (n=259) n=128 n=119 n=12
Model 1 1 (Ref.) 1.4 (1.1 to 1.8) 3.0 (1.6 to 5.5) 0.001
Model 2 1 (Ref.) 1.5 (1.2 to 2.0) 3.6 (1.7 to 7.5) <0.0001
Model 3 1 (Ref.) 1.3 (1.0 to 1.8) 3.3 (1.3 to 8.3) 0.024
All
Events (n=436) n=189 n=208 n=39
Model 4
Mitral Doppler flow
Normal 1 (Ref.) 1.4 (1.1 to 1.7) 3.1 (2.1 to 4.8) <0.0001*
Abnormal 1.2 (0.9 to 1.7) 1.8 (1.3 to 2.4) 3.5 (1.8 to 6.7)
Model 5
Mitral Doppler flow
Normal 1 (Ref.) 1.5 (1.2 to 2.0) 4.8 (2.9 to 7.8) <0.0001*
Abnormal 1.3 (0.9 to 1.8) 2.1 (1.5 to 3.0) 3.7 (1.6 to 8.7)
The Tromsø Study, 1994–2010.
*p Value for trend is calculated for six groups of LA size and mitral Doppler flow combined. Description can be found in the Methods section.
Model 1: adjusted for age and sex (not in sex-specific models).
Model 2: as Model 1+height, body mass index, hypertension, diabetes, palpitation.
Model 3: as Model 2, participants with coronary heart disease, valvular heart disease, heart failure or hypertrophy at baseline excluded.
Model 4: as Model 1.
Model 5: as Model 2.
Mitral Doppler flow—normal: E/A ratio 0.75–1.5 and E-wave deceleration time (EDT >140 ms; abnormal: E/A ratio <0.75 or >1.5 or EDT <140 ms.
Ref; reference.
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documented AF. A reproducibility study was performed to valid-
ate echocardiographic data.
Limitations
Although a detailed search method was used, there may be
people with undiagnosed AF. Subjects with asymptomatic or
paroxysmal AF often fail to get their arrhythmia documented or
are never hospitalised. The Tromsø Study did not acquire data
on tissue Doppler or mitral Doppler during Valsalva manoeuvre,
and LA size was best evaluated with estimation of volume.28
Probably, this attenuated our HR estimates. The external validity
refers to Caucasians and may not be generalisable to others.
CONCLUSION
Enlarged LA as a measure of diastolic dysfunction was inde-
pendently associated with an increased risk of clinical AF in
both sexes, and adding measures of abnormal diastolic ﬂow
increased the predictive ability signiﬁcantly.
Key messages
What is already known on this subject?
Left atrial (LA) size and mitral Doppler indices have been
associated with atrial ﬁbrillation (AF) in subgroups of elderly
and subjects with prevalent disease and in studies with
relatively short follow-up.
What might this study add?
This study provides sex-speciﬁc long-term results for the association
between LA and AF in a large population-based cohort. Men and
women with a severely enlarged LA had a fourfold increased risk of
developing AF. Adding measures of abnormal diastolic ﬂow
increased the predictive ability signiﬁcantly, but unadjusted mitral
Doppler indices did not show any association with AF risk.
How might this impact on clinical practice?
Enlarged LA is a sign of chronically increased LA pressure and a
risk factor for AF and thereby for subsequent stroke. A closer
clinical monitoring of patients with a CHA2DS2-VASc score >1
together with good patient education of the clinical signs of AF is
probably the appropriate measure to improve stroke prophylaxis.
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